The ability of nanoparticles to evade the immune system, cross biological barriers, and localize at the target tissue ultimately determines their therapeutic potential. Leukocytes naturally encompass all of these features and, therefore, provide great inspiration in biomimetic vectors. Herein, we present a hybrid drug delivery system, termed leukolike vectors, composed of a synthetic nanoporous silicon core cloaked with cellular membranes derived from circulating white blood cells. These particles possess the ability to avoid clearance by the mononuclear phagocyte system, interact with endothelial cells through receptor-ligand interaction, and effi ciently deliver a therapeutic payload to infl amed endothelia. Furthermore, in vivo studies revealed an ability to retain the leukocyte membrane's biological function following systemic administration, demonstrating prolonged circulation and improved tumor targeting abilities.
Furman, N., Molinaro, R., Parodi, A., Evangelopoulos, M., Martinez, J., Corbo, C., et al. (2016). Case Study: Application of leukoLike technology to camouflage nanoparticles from the immune recognition. In Handbook of Immunological properties of engineered nanomaterials (pp. 43-68). World Scientific Publishing Co. Pte. Ltd. [10.1142/9677].
Case Study: Application of leukoLike technology to camouflage nanoparticles from the immune recognition
Corbo, C;
2016
Abstract
The ability of nanoparticles to evade the immune system, cross biological barriers, and localize at the target tissue ultimately determines their therapeutic potential. Leukocytes naturally encompass all of these features and, therefore, provide great inspiration in biomimetic vectors. Herein, we present a hybrid drug delivery system, termed leukolike vectors, composed of a synthetic nanoporous silicon core cloaked with cellular membranes derived from circulating white blood cells. These particles possess the ability to avoid clearance by the mononuclear phagocyte system, interact with endothelial cells through receptor-ligand interaction, and effi ciently deliver a therapeutic payload to infl amed endothelia. Furthermore, in vivo studies revealed an ability to retain the leukocyte membrane's biological function following systemic administration, demonstrating prolonged circulation and improved tumor targeting abilities.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.